CorMedix Inc. (CRMD) SEC Filings & Earnings Calls

Regulatory risk: FDA may not approve sNDA or may require additional data.

“Forward-looking statements note risk that FDA may not approve sNDA, may request additional data, or may extend review.”

Post-TDAPA reimbursement environment for DefenCath remains a risk.

“Management notes navigating post-TDAPA reimbursement environment with discipline.”

Securities litigation legal fees partially offset by insurance reimbursement.

“Recognized $4.2 million of expected insurance reimbursement of legal fees for securities litigation.”

Reimbursement Risk

“On July 1, 2026, DefenCath’s TDAPA reimbursement transitioned into a post-TDAPA Add-On Adjustment... the level of reimbursement... significantly declined, and as a result, CorMedix expects a corresponding reduction to its net pricing, resulting in lower net sales, for DefenCath in the second half of 2026 relative to historical periods.” · word for word

Tariff Risk

“On April 2, 2026, the U.S. government issued an executive order imposing new tariffs on certain imported goods, including active pharmaceutical ingredients (“APIs”), excipients, and packaging materials commonly used in the pharmaceutical industry. The Company is currently assessing the impact of the tariffs, which may adversely affect our gross margins and o” · word for word

Integration Risk

“The ability of the combined company to achieve the identified synergies; the ability to integrate the Melinta business into CorMedix and realize the anticipated strategic benefits of the transaction within the expected time-frames or at all.” · word for word

Derivative lawsuit settlement; potential financial and reputational impact, but terms not disclosed.

“Preliminary approval of settlement; final hearing September 23, 2026.”

Material weakness in internal control over financial reporting related to review of non-routine transactions.

“Material weakness in internal control over financial reporting as initially reported in Item 9A of 10-K for FY2025.”

Reliance on single product MINOCIN for revenue; patent protection is critical

“patents covering its product MINOCIN for Injection are valid and infringed” · word for word

Pending TDAPA expiration may impact DefenCath revenue.

“DefenCath continues to exceed expectations despite pending TDAPA expiration.” · word for word

Clinical trial enrollment delays for TPN indication.

“Ongoing Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients continues to enroll patients and is currently trending to completion in 2028.” · word for word

DefenCath reimbursement reduction

“On July 1, 2026, DefenCath’s TDAPA reimbursement transitions into a post-TDAPA Add-On Adjustment... the level of reimbursement provided to institutions treating dialysis patients will significantly decline, and as a result, CorMedix expects a corresponding reduction to its net pricing for DefenCath in the second half of 2026.” · word for word

Tariff impact on gross margins

“On April 2, 2026, the U.S. government issued an executive order imposing new tariffs on certain imported goods, including active pharmaceutical ingredients (“APIs”), excipients, and packaging materials commonly used in the pharmaceutical industry. The Company is currently assessing the impact of the tariffs, which may adversely affect our gross margins and o” · word for word

Integration risk from Melinta acquisition

“The ability of the combined company to achieve the identified synergies; the ability to integrate the Melinta business into CorMedix and realize the anticipated strategic benefits of the transaction within the expected time-frames or at all.” · word for word

Reimbursement Transition Risk

“As we enter 2026, we anticipate a transitional year with the expiration of TDAPA reimbursement for DefenCath and the CMS implementation of the post-TDAPA Add-On phase of reimbursement for the product.” · word for word

Single Product Concentration (pre-Melinta)

“The acquisition provided us with a base portfolio of durable specialty injectable products... This transition underscores the importance and rationale for the Melinta acquisition in 2025”

Preferred Stock Voting Complexity

“A stockholder raised a question about whether certain historical amendments to our certificates of designation for preferred stock were properly authorized.” · word for word

Clinical trial data may change as more patient data become available; regulatory approval not guaranteed.

“topline data from CorMedix's and its partners' clinical trials, including the ReSPECT study, that CorMedix announces or publishes from time to time may change as more patient data become available” · word for word

Inadvertent guidance error on earnings call could indicate communication control issues.

“notwithstanding an inadvertent statement regarding this guidance on its March 5, 2026 earnings call referring to a range of $100 million to $125 million” · word for word

Tax expense of $42.4M in Q4 due to utilization of deferred tax assets, impacting net income.

“Net income for the fourth quarter of 2025 included tax expense...of $42.4 million” · word for word

Reimbursement Transition Risk

“As a result of the methodology utilized by CMS, the level of reimbursement provided to institutions treating dialysis patients will significantly decline, and as a result, we expect a corresponding reduction to net pricing for DefenCath in the third and fourth quarters of 2026.” · word for word

Single-Source Supplier Risk

“As of December 31, 2025, the Company has one FDA-approved source (contract manufacturing organization, or 'CMO') for each of its two key active pharmaceutical ingredients ('APIs'), taurolidine and heparin sodium, respectively.” · word for word

Customer Concentration Risk

“Customer A 38 % 86 %, Customer B 20 % 9 %, Customer C 21 % 0 %” · word for word

Reimbursement transition risk for DefenCath

“DefenCath's TDAPA reimbursement transitions to post-TDAPA Add-On Adjustment in July 2026, leading to significant price decline in H2 2026.”

Clinical trial execution risk

“Phase 3 ReSPECT study data expected in Q2 2026; Phase 3 taurolidine/heparin study completion in early 2027.”

Integration risk from Melinta acquisition; one-time costs and potential execution challenges.

“$12.7 million of non-recurring costs, including transaction, integration and severance costs associated with the Melinta acquisition” · word for word

Dependence on DefenCath for revenue; any competitive or regulatory changes could impact.

“DefenCath sales contributed $88.8 million of net revenue in the quarter.” · word for word

Potential dilution from equity plan

“Potential Dilution to Stockholders of 4,312,000 Additional Shares Requested under the 2022 Plan as a Percentage of Fully Diluted Shares of Common Stock 4.6 %” · word for word

Legal uncertainty regarding preferred stock amendments

“A stockholder who recently acquired a small number of shares of our stock has raised a question regarding whether the approval of the holders of the then-outstanding shares of common stock was required to duly authorize the COD Amendments.” · word for word